Among the most critical decisions for optimizing franchise value is pricing, which demands specialized expertise. Strategic Pricing groups in pharmaceutical and biotech companies cut through the institutional complexity to identify critical aspects of the portfolio strategy and support that strategy with sound pricing recommendations. Vice President Rhett Johnson discusses how an effective Strategic Pricing group possesses the regulatory knowledge, functional expertise, strategic vision, and portfolio-wide perspective to lead the organization toward maximum portfolio value. To read this article, click here:
CRA recognized in Chambers 2026 for litigation support and crisis & risk management
Charles River Associates has been recognized in the 2026 Chambers Litigation Support and Crisis & Risk Management Guides, including a Band 1 global ranking...